Pharmaceuticals
Bridging the Healthcare Gap in Thailand and Beyond with the Belt and Road Initiative
BANGKOK, Oct. 18, 2023 /PRNewswire/ -- "I have a dream that everyone should have the ability to access medical care equally," says Oraphan Wanacharoen (Ice), BGI Genomics Field Application Scientist. "It's very challenging to achieve such a goal inThailand. With the advanced technology of the com...
2023-10-18 08:21
1807
Bio4t2 announces trial evaluating repeat infusions of CAR-T targeting solid tumors without lymphodepletion
SAN DIEGO and SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Bio4t2® received regulatory approvals to repeatedly administer patients with T cells engineered to express a chimeric antigen receptor (CAR) targeting BT-001, an antigen on solid tumors identified using the PrismCore™ platform. The CAR-T, term...
2023-10-17 23:17
1731
SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement
ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedica...
2023-10-17 17:00
3264
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (...
2023-10-16 07:48
989
Offering broader access to sustainable and scalable pharma-grade saponin adjuvants
SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant's proprietary 100% sustainable Q-SAP™ technology, and the signing of an exclusive commercial agreement to accelerate global adoption of their high-purity saponin adjuvants ...
2023-10-13 21:47
2532
GenScript ProBio Congratulates ABL Bio's IND Clearance of ABL103 Program from MFDS
SEOUL, South Korea, Oct. 13, 2023 /PRNewswire/ -- Recently, ABL Bio, a partner of GenScript ProBio, announced the Ministry of Food and Drug Safety (MFDS) cleared of its clinical trial application for innovative bispecific antibody program (B7H4x4-1BB) in solid tumor. GenScript ProBio warmly exten...
2023-10-13 09:00
1911
Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research
Metabolon's newest panels help academic and commercial researchers reveal complex biological insights about liver fibrosis and kidney dysfunction MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of lif...
2023-10-12 19:57
1321
Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023
HANGZHOU and SHAOXING, China, Oct. 11, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Der...
2023-10-11 08:10
1765
SAFETYscan47: A Valuable Component in Revolutionizing Chemical Risk Assessments for Global Health and Safety
SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, today announced its SAFETYscan®47 platform as a New Approach Methodology (NAM), part of a standardized framework aiming to revolutionize chemical risk a...
2023-10-10 23:10
1665
Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-- STX-721 is characterized by high selectivity and a potentially best-in-class profile -- -- Scorpion's second program to enter clinical development this year -- -- One of two EGFR programs being developed with Pierre Fabre Laboratories -- BOSTON and CASTRES, France, Oct. 10, 2023 /PRNewswire/...
2023-10-10 18:00
1376
AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL
Expands Portfolio of Cataract Surgery Solutions for Patients in Greater China to New Extended Monofocal Segment AffaMed Therapeutics and SIFI Leadership Celebrate Strong Progress of the AffaMed Technologies Joint-Venture BEIJING, Oct. 10, 2023 /PRNewswire/ -- AffaMed Technologies ("AffaMed"), a ...
2023-10-10 09:00
2170
Kaneka Files Patent Infringement Lawsuit Against CoCrystal
TOKYO, Oct. 10, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit inthe United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and mon...
2023-10-10 03:47
2018
Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration
ROCKVILLE, Md. and SUZHOU, China, Oct. 9, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-10-09 08:00
5494
Xinhua Silk Road: Xinhua-Hengshan Astragalus Membranaceus Market Index unveiled in China's Shanxi
BEIJING, Oct. 8, 2023 /PRNewswire/ -- The Xinhua-Hengshan Astragalus
Membranaceus Market Index was recently unveiled in Hunyuan County, northChina's
Shanxi Province.
2023-10-08 10:02
5067
Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023
SHANGHAI, Oct. 5, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") presented new biomarker and subgroup analyses from Nefecon®'s Phase 3 NefIgArd study in both posters and ...
2023-10-05 07:33
1808
Amcor's AmSky™ and AmPrima™ earn Walmart's 'Circular Connector' seal of approval
ZURICH, Oct. 4, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global
leader in developing and producing responsible packaging solutions, has been
recognized for itsAmSky™
2023-10-04 23:55
5183
Large-scale proteomics in population-based studies from UK and Iceland
REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome an...
2023-10-04 23:00
1974
Kensing to Acquire AOM
Acquisition expands Kensing's Natural Vitamin E and phytosterols product offerings. KANKAKEE, Ill., Oct. 4, 2023 /PRNewswire/ -- Kensing, LLC ("Kensing" or the "Company"), a leading manufacturer of Natural Vitamin E, Plant Sterols and high-purity surfactants, and a portfolio company owned by an ...
2023-10-04 21:00
2279
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Osemitamab (TST001) on Track to Become a Global Therapy that Elevates the Current Standard of Care for HER2-Negative G/GEJ Adenocarcinoma PRINCETON, N.J. and SUZHOU, China, Oct. 4, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical co...
2023-10-04 08:00
1769
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
* This Emergency Use Authorization and CDC recommendation makes Novavax's vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. * Novavax expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid * Fin...
2023-10-04 04:25
1891
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 320 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
9520
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
5449
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
5354
Sobha Developers bring to Singapore an Exclusive Dubai Property Showcase
2024-05-11 17:48
4487
